About Investing News Network

Investing News Network

The Investing News Network® (INN) is a rapidly growing network of focused publications.

We provide independent, unbiased news and education for investors in targeted niches.

For investors who are comfortable taking the next step, we offer the opportunity to connect with trusted companies providing investment opportunities.

For these trusted companies, we connect them with investors who are educated in the specific opportunities in that niche and who are ready to engage.

Articles

Life Science Investing

Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

Revive Therapeutics (TSX VENTURE:RVV)(OTCQB:RVVTF), today announced the Company has entered into a term sheet agreement with InMed Pharmaceuticals Inc. (“InMed”) for the discovery and development of cannabinoid-based therapies targeting kidney diseases.

“I am very excited to be partnering with InMed and utilizing their proprietary Bioinformatics Database Assessment Tool, an in-silico technology

Life Science Investing

NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.

Fourth Quarter 2016 Highlights:

140% increase in clinical genetic testing volume(1)
122% increase in consolidated revenue to $60.5 million
11% reduction in average cost per clinical genetic

Life Science Investing

Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational intratumoral therapy, G100, for the treatment of follicular non-Hodgkin’s lymphoma.

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products

Life Science Investing

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada

Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc. (TSX:GUD) (Knight), a leading Canadian specialty pharmaceutical company, today announced that Knight’s New Drug Submission (NDS) for ILUVIEN® has been accepted for review by Health Canada. ILUVIEN (fluocinolone acetonide intravitreal

Life Science Investing

Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information, announced today that it has received approval for a $1.0 million gross tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. After expenses and fees,

Life Science Investing

Align Technology Announces Digital Implant Workflow for Its iTero(R) Scanners With Nobel Biocare(R) and Elos Medtech Scan Bodies

Align Technology, Inc. (NASDAQ: ALGN) today expanded workflow options for the iTero® intraoral scanner by announcing the availability of a digital workflow for Nobel Biocare implants. iTero customers can now order Nobel Biocare implant cases through their dental labs. Dental labs can now order NobelProcera® single-unit restorations for their doctors,

Life Science Investing

VBI Vaccines Receives Positive Response from Health Canada’s Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (“VBI”) announced today that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada expressed its general support and acceptance of the company’s development path for its Sci-B-Vac™ vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application (“CTA”) meeting. A complete CTA must

Tech Investing

Mitel Surpasses Three Million Cloud Subscribers

Mitel® (Nasdaq:MITL) (TSX:MNW), a global leader in enterprise communications, announced today the addition of more than one million new cloud subscribers in 2016, tipping its cloud business past the three million user mark to reach another industry milestone. The company still holds the lead in business cloud communications with more

Life Science Investing

Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma

Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the successful completion of Cohort 3 and initiation of Cohort 4 in the company’s Phase I clinical study of CLR 131 in patients with relapsed and refractory multiple myeloma.

The fourth cohort of the Phase 1 study will consist

Life Science Investing

ToolGen Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing

ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.

Results from the study entitled “In vivo genome editing with a small Cas9 orthologue derived

Life Science Investing

Inspyr Therapeutics Initiates Mipsagargin Combination Therapy Program for Gastric Cancer

Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company developing novel therapeutics for the treatment of cancer, today announced the initiation of the second development program for Mipsagargin as part of a combination therapeutic approach.  This new program is focused on the treatment of gastric cancer.

As part of the Company’s development plan